Issue

Vol. 66 No. 3: Issue 3

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Verification of expression of LINC00648 in the serum of lung cancer patients by TCGA database

https://doi.org/10.14715/cmb/2020.66.3.15
Ling Zhao
Department of Operating Room, Gaomi City People's Hospital, Gaomi 261500, P.R. China
Mingxu Gao
Department of Medical Laboratory, Gaomi City People's Hospital, Gaomi 261500, P.R. China
Xiujuan Zhao
Department of Respiratory medicine, Gaomi City People's Hospital, Gaomi 261500, P.R. China

Corresponding Author(s) : Xiujuan Zhao

xiujuanzhao@mail.ru

Cellular and Molecular Biology, Vol. 66 No. 3: Issue 3

Abstract

TCGA data were used to verify the expression of LINC00648 in lung cancer patients to provide a reference for clinical practice.  Lung cancer transcriptome data were downloaded by the TCGA database and LINC00648 data were extracted for analysis. Fifty-two patients with lung cancer diagnosed in our hospital from May 2014 to March 2016 were collected as the patient group and 30 normal people as the control group. RT-qPCR was used to detect the expression of LINC00648 in serum, follow up of patients was carried out, and bioinformatics was used to analyze the potential mechanism of LINC00648. LINC00648 was highly expressed in lung cancer. Lymphatic metastasis and probability of low differentiation were significantly increased, and the overall survival rate of highly expressed patients with lung cancer was reduced and the prognosis was poor. LINC00648 had 17 potential miR-targeted and 78 miR-targeted mRNAs. LINC00648 was found to have participated in SMAD binding, transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding, PDZ domain binding, cytokine binding, activin binding, RNA polymerase II activating transcription factor binding, transforming growth factor-beta receptor binding, etc. LINC00648 participated in the signal pathways of the Hippo signaling pathway, Transcriptional misregulation in cancer, MAPK signaling pathway, Proteoglycans in cancer. There were 55 co-expression pairs in PPI protein co-expression analysis, of which KIF11 was the most common.  High expression of LINC00648 in lung cancer patients indicates poor prognosis of patients and is expected to become a potential diagnostic marker for lung cancer.

Keywords

TCGA LINC00648 Lung cancer Bioinformatics analysis.
Zhao, L., Gao, M., & Zhao, X. (2020). Verification of expression of LINC00648 in the serum of lung cancer patients by TCGA database. Cellular and Molecular Biology, 66(3), 101–108. https://doi.org/10.14715/cmb/2020.66.3.15
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Torre L A, Siegel R L, Jemal A. Lung cancer statistics[M]//Lung cancer and personalized medicine. Springer, Cham. 2016: 1-19.
  2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.
  3. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10: 1243–1260.
  4. Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest. 2017; 151: 193-203.
  5. International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006; 355: 1763-1771.
  6. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.J Natl Cancer Inst. 1996; 88: 1210-1215.
  7. Nesbitt JC, Putnam Jr JB, Walsh GL, et al. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg. 1995; 60: 466-472.
  8. Cronin KA, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer. 2014; 120: 3755.
  9. Henschke CI, Yip R, Smith JP, et al. CT screening for lung cancer: part-solid nodules in baseline and annual repeat rounds. AJR Am J Roentgenol. 2016; 207: 1176-1184.
  10. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409.
  11. Xie Y, Zhang Y, Du L, et al. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non"small cell lung cancer. Mol Oncol. 2018; 12: 648-658.
  12. Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018; 18: 5.
  13. Romano G, Veneziano D, Acunzo M, et al. Small non-coding RNA and cancer. Carcinogenesis. 2017; 38: 485-491.
  14. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015; 15: 321.
  15. Meng S, Zhou H, Feng Z, et al. CircRNA: functions and properties of a novel potential biomarker for cancer. Mol Cancer. 2017; 16: 94.
  16. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016; 29: 452-463.
  17. Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017; 36: 5661.
  18. Fang Z, Chen W, Yuan Z, et al. LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed Pharmacother. 2018; 101: 536-542.
  19. Li T, Mo X, Fu L, et al. Molecular mechanisms of long noncoding RNAs on gastric cancer. Oncotarget. 2016; 7: 8601.
  20. Huo X, Han S, Wu G, et al.. Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells. Mol Cancer. 2017; 16: 165.
  21. Yue B, Qiu S, Zhao S, et al. LncRNA"ATB mediated E"cadherin repression promotes the progression of colon cancer and predicts poor prognosis. J Gastroenterol Hepatol. 2016; 31: 595-603.
  22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods. 2001; 25: 402-408.
  23. Chiu H S, Somvanshi S, Patel E, et al.. Pan-cancer analysis of lncRNA regulation supports their targeting of cancer genes in each tumor context. Cell Rep. 2018; 23: 297-312. e12.
  24. Nie W, Ge H, Yang X, et al. LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p. Cancer Lett. 2016; 371: 99-106.
  25. Cui Y, Zhang F, Zhu C, et al. Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway. Oncotarget. 2017; 8: 17785.
  26. Jiang N, Meng X, Mi H, et al. Circulating lncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer. Clin Chim Acta. 2018; 486: 26-33.
  27. Chen W, Hang Y, Xu W, et al.. BLACAT1 predicts poor prognosis and serves as oncogenic lncRNA in small"cell lung cancer. J Cell Biochem. 2019; 120: 2540-2546.
  28. Bracht JWP, Mayo-de-las-Casas C, Berenguer J, et al. The present and future of liquid biopsies in non-small cell lung cancer: combining four biosources for diagnosis, prognosis, prediction, and disease monitoring. Curr Oncol Rep. 2018; 20: 70.
  29. He B, Bai Y, Kang W, et al. LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p. Am J Cancer Res. 2017; 7: 1704.
  30. Qi X, Zhang D H, Wu N, et al. ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015; 52: 710-718.
  31. Song C, Zhang J, Qi H, et al. The global view of mRNA-related ceRNA cross-talks across cardiovascular diseases. Sci Rep. 2017; 7: 10185.
  32. Liu C, Yang Z, Deng Z, et al. Upregulated lncRNA ADAMTS9"AS2 suppresses progression of lung cancer through inhibition of miR"223"3p and promotion of TGFBR3. IUBMB Life. 2018; 70: 536-546.
  33. Ahmadi A, Khansarinejad B, Hosseinkhani S, et al. miR-199a-5p and miR-495 target GRP78 within UPR pathway of lung cancer. Gene. 2017; 620: 15-22.
  34. Chen W, Zhang E, Zhong Z, et al. MiR-199b-5p suppresses proliferation and invasion of non-small cell lung cancer (NSCLC) via HER2/PI3K/Akt pathway. Int J Clin Exp Pathol. 2016; 9: 6203-6209.
  35. Andl T, Zhang Y. Reaping Wnt after calming Hippo: Wnt and Hippo signaling cross paths in lung cancer. J Thorac Dis. 2017; 9: 4174.
  36. Hamamoto R, Nakamura Y. Dysregulation of protein methyltransferases in human cancer: an emerging target class for anticancer therapy. Cancer Sci. 2016, 107: 377-384.
  37. Kang K A, Piao M J, Hewage S R K M, et al. Fisetin induces apoptosis and endoplasmic reticulum stress in human non-small cell lung cancer through inhibition of the MAPK signaling pathway. Tumour Biol. 2016; 37: 9615-9624.
  38. Theocharis AD, Karamanos NK. Proteoglycans remodeling in cancer: underlying molecular mechanisms. Matrix Biol. 2017.
  39. Schneider MA, Christopoulos P, Muley T, et al. AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients. Int J Oncol. 2017, 50: 365-372.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 868 Download : 522